US3962432A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment of calcium disorders using aminoalkane-diophosphonic acids
Assignee: Henkel AG and Co KGaA
•
Filing: 1974-12-03
•
Granted: 1976-06-08
•
Expires: 1994-12-03
Abstract
Abstract A method for the treatment of diseases relating to the abnormal deposition or dissolution of difficulty soluble calcium salts in the body or mouths of warm-blooded animals which consists of administering orally, parenterally or topically to said warm-blooded animals, a safe but effective amount of at least one pharmacologically acceptable aminoalkane diphosphonic acid derivative or a water-soluble salt thereof.
Inventors
- 👤 Manfred Schmidt-Dunker
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 21:18
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K8/00; A61K8/18; A61K8/30; A61K8/55; A61Q; A61Q11/00; C; C07; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3839; C07F9/3873
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
118 words
A method for alleviating conditions caused by the abnormal deposition or dissolution of difficulty soluble calcium salts in the body of warm-blooded animals having said conditions which consists in administering orally or parenterally to said warm-blooded animals, from 0.05 to 500 mg.kg. of the animal body weight of a pharmacologically acceptable aminoalkane-diphosphonic acid derivative selected from the group consisting of (A) at least one aminoalkane-diphosphonic acid of the formula: ##EQU5## wherein R 1 and R 2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and (B) a pharmacologically acceptable water-soluble salt of (A), said derivative being administered in the form of tablets, pills or capsules, or as injectable solutions.
Claim 2
Independent Claim
118 words
A method for alleviating conditions caused by the abnormal deposition or dissolution of difficulty soluble calcium salts in the body of warm-blooded animals having said conditions which consists in administering orally or parenterally to said warm-blooded animals, from 0.05 to 500 mg.kg. of the animal body weight of a pharmacologically acceptable aminoalkane-diphosphonic acid derivative selected from the group consisting of (A) at least one aminoalkane-diphosphonic acid of the formula: ##EQU5## wherein R 1 and R 2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and (B) a pharmacologically acceptable water-soluble salt of (A), said derivative being administered in the form of tablets, pills or capsules, or as injectable solutions.
Claim 3
Dependent Claim
27 words
The method of claim 1, wherein said derivative is selected from the group consisting of (A) 3-amino-1-hydroxypropane-1,1-diphosphonic acid and (B) a pharmacologically acceptable water-soluble salt of (A).
Claim 4
Dependent Claim
85 words
A pharmaceutical composition for alleviating conditions caused by the abnormal deposition or dissolution of difficultly soluble calcium salts consisting essentially of a effective amount of a pharmacologically acceptable aminoalkane-diphosphonic acid derivative selected from the group consisting of A. an aminoalkane-diphosphonic acid of the formula ##EQU6## wherein R 1 and R 2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and B. a pharmacologically acceptable water-soluble salt of (A), and a major amount of pharmacologically acceptable excipients.
Claim 5
Dependent Claim
85 words
A pharmaceutical composition for alleviating conditions caused by the abnormal deposition or dissolution of difficultly soluble calcium salts consisting essentially of a effective amount of a pharmacologically acceptable aminoalkane-diphosphonic acid derivative selected from the group consisting of A. an aminoalkane-diphosphonic acid of the formula ##EQU6## wherein R 1 and R 2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and B. a pharmacologically acceptable water-soluble salt of (A), and a major amount of pharmacologically acceptable excipients.
Claim 6
Dependent Claim
28 words
The pharmaceutical composition of claim 3, wherein said derivative is selected from the group consisting of (A) 3amino-1-hydroxypropane-1,1-diphosphonic acid and (B) a pharmacologically acceptable water-soluble salt of (A).
Claim 7
Dependent Claim
69 words
A pharmaceutical composition consisting essentially of from 0.01% to 5% by weight of an aminoalkane-diphosphonic acid derivative selected from the group consisting of A. an aminoalkane-diphosphonic acid of the formula ##EQU7## wherein R 1 and R 2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and B. a pharmacologically acceptable water-soluble salt of (A), and the remainder pharmacologically acceptable excipients.
Claim 8
Dependent Claim
69 words
A pharmaceutical composition consisting essentially of from 0.01% to 5% by weight of an aminoalkane-diphosphonic acid derivative selected from the group consisting of A. an aminoalkane-diphosphonic acid of the formula ##EQU7## wherein R 1 and R 2 are each selected from the group consisting of hydrogen and alkyl having 1 to 3 carbon atoms, and B. a pharmacologically acceptable water-soluble salt of (A), and the remainder pharmacologically acceptable excipients.
Claim 9
Dependent Claim
28 words
The pharmaceutical composition of claim 5, wherein said derivative is selected from the group consisting of (A) 3-amino-1-hydroxypropane-1,1-diphosphonic acid and (B) a pharmacologically acceptable water-soluble salt of (A).
Claim 10
Dependent Claim
17 words
The pharmaceutical composition of claim 5, wherein said pharmacologically acceptable water-soluble salt is an alkali metal salt.
Claim 11
Dependent Claim
12 words
A composition according to claim 5 wherein the excipient is orally acceptable.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-08 | 1979-12-08 | 1980-06-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-08 | 1983-12-08 | 1984-06-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-08 | 1987-12-08 | 1988-06-08 | $7700.00 | Window Closed / Lapsed |